Cas:900156-22-1 tert-butyl 2-methoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 2-methoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate

CAS.NO:900156-22-1

Synonyms:2-Methoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid tert-butyl ester;tert-butyl2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate

Molecular Formula:C₁₃H₁₉N₃O₃

Molecular Weight:265.30800

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:64.55000

Exact Mass:265.14300

LogP:1.71630

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Methoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid tert-butyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid tert-butyl ester Use and application,tert-butyl2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate technical grade,usp/ep/jp grade.

Related News: Ireland is globally recognised as a hub for the Life Sciences sector and this news is a real vote of confidence in us and our capacity.” (R)-5-[(tert-butyldimethylsilyloxy)methyl]-5-(hydroxymethyl)tetrahydro-2-furanone manufacturers Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion. cis-p-Isobornyl-cyclohexanol-acetat suppliers Biocatalytic processing offers many advantages over using conventional metal catalysts. The superior enantio- and regioselectivity of enzymes results in higher yields of purer product—typically comprising just a single enantiomer that has been modified on only a specific site. diethyl 2-((1-((2-(4-(tert-butyl)thiazol-2-yl)benzofuran-5-yl)methyl)-3-cyano-1H-indol-5-yl)methyl)malonate vendor & factory After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease.,The client needed full development and product readiness with an extremely short supply of the API. In addition, the scale-up batch was small because of the low volume of product demands of their orphan drug.